OBJECTIVES: This study aims to assess the clinical and economic impact of ketoanalogues of essential aminoacids (Ketosteril) in the management of CKD in the context of the Kazakhstani healthcare system.

METHODS: Our analysis incorporated annual direct costs per patient in the management of CKD in adult patients comparing Ketosteril with a placebo. We conducted an economic evaluation focusing on the cost-effectiveness and one-way sensitivity analyses up to 90%. The change in QALYs was used as the primary endpoint of measure.

RESULTS: The findings of the cost-effectiveness analysis unveiled a compelling cost-effectiveness advantage of Ketosteril over the placebo, in the CKD management. Ketosteril resulted in a better ratio of the main cost-effectiveness ratio (CER) parameters and a negative incremental cost-effectiveness ratio (ICER). For the QALY, the CER was USD3218 versus USD6788 and the ICER was –USD6779. Our findings were confirmed with the sensitivity analysis.

CONCLUSIONS: Our findings provide strong evidence supporting effectiveness and safety profile of using ketoanalogues of essential aminoacids for individuals with CKD. These crucial understandings have promoted its adoption into numerous global therapeutic practices. Furthermore, Ketosteril's advantageous pharmacoeconomic characteristics suggest its recommendation for the management of CKD in Kazakhstan.